SKYE BIOSCIENCE DL -,001 Aktie

Squarepoint Ops LLC bought a new stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 13,546 shares of the company’s stock, valued at approximately $38,000. Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in Skye Bioscience during the fourth quarter valued at approximately $29,000. Wells Fargo & Company MN increased its holdings in Skye Bioscience by 49.0% during the fourth quarter. Wells Fargo & Company MN now owns 11,199 shares of the company’s stock valued at $32,000 after buying an additional 3,684 shares during the last quarter. Two Sigma Advisers LP purchased a new stake in Skye Bioscience during the fourth quarter valued at approximately $32,000. Jane Street Group LLC increased its holdings in Skye Bioscience by 195.5% during the fourth quarter. Jane Street Group LLC now owns 36,057 shares of the company’s stock valued at $102,000 after buying an additional 23,857 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in Skye Bioscience by 37.4% during the fourth quarter. Bank of America Corp DE now owns 39,257 shares of the company’s stock valued at $111,000 after buying an additional 10,696 shares during the last quarter. 21.09% of the stock is owned by hedge funds and other institutional investors. Skye Bioscience Price Performance SKYE opened at $2.37 on Wednesday. The firm has a market cap of $73.41 million, a P/E ratio of -2.89 and a beta of 1.69. Skye Bioscience, Inc. has a 1-year low of $1.14 and a 1-year high of $11.16. The company has a 50 day simple moving average of $2.07 and a two-hundred day simple moving average of $1.96. Skye Bioscience (NASDAQ:SKYE – Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. Equities analysts anticipate that Skye Bioscience, Inc. will post -1.04 earnings per share for the current year. Wall Street Analysts Forecast Growth A number of equities analysts have weighed in on SKYE shares. William Blair reiterated an “outperform” rating on shares of Skye Bioscience in a research report on Tuesday, May 20th. Craig Hallum dropped their price target on shares of Skye Bioscience from $18.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $16.60. Check Out Our Latest Stock Analysis on SKYE Skye Bioscience Company Profile (Free Report) Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.» Mehr auf defenseworld.net

Squarepoint Ops LLC acquired a new stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 13,546 shares of the company’s stock, valued at approximately $38,000. Other institutional investors and hedge funds have also recently made changes to their positions in the company. Braidwell LP purchased a new stake in shares of Skye Bioscience during the 4th quarter valued at $2,337,000. Deutsche Bank AG raised its position in shares of Skye Bioscience by 365.0% during the 4th quarter. Deutsche Bank AG now owns 40,835 shares of the company’s stock valued at $116,000 after buying an additional 32,054 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Skye Bioscience by 20.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 62,363 shares of the company’s stock valued at $176,000 after buying an additional 10,707 shares in the last quarter. Barclays PLC raised its position in Skye Bioscience by 20.3% in the 4th quarter. Barclays PLC now owns 69,620 shares of the company’s stock worth $198,000 after purchasing an additional 11,731 shares during the period. Finally, Schonfeld Strategic Advisors LLC raised its position in Skye Bioscience by 48.3% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 1,422,741 shares of the company’s stock worth $4,026,000 after purchasing an additional 463,644 shares during the period. Hedge funds and other institutional investors own 21.09% of the company’s stock. Analyst Ratings Changes A number of equities analysts recently commented on SKYE shares. Craig Hallum decreased their target price on shares of Skye Bioscience from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. William Blair reiterated an “outperform” rating on shares of Skye Bioscience in a research report on Tuesday, May 20th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Skye Bioscience currently has an average rating of “Buy” and an average price target of $16.60. Check Out Our Latest Analysis on Skye Bioscience Skye Bioscience Stock Up 1.3% Shares of NASDAQ:SKYE opened at $2.37 on Wednesday. The stock has a market cap of $73.41 million, a PE ratio of -2.89 and a beta of 1.69. The company’s fifty day moving average is $2.07 and its 200 day moving average is $1.96. Skye Bioscience, Inc. has a 52 week low of $1.14 and a 52 week high of $11.16. Skye Bioscience (NASDAQ:SKYE – Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. Sell-side analysts anticipate that Skye Bioscience, Inc. will post -1.04 EPS for the current year. Skye Bioscience Company Profile (Free Report) Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.» Mehr auf defenseworld.net

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.» Mehr auf zacks.com